Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Bio-Path Holdings, Inc.
Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors
August 21, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Reports Second Quarter 2024 Financial Results
August 15, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024
August 08, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Provides Clinical Update and Expansion Plans
July 08, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
June 14, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
June 05, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
June 04, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting
June 03, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
May 24, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Reports First Quarter 2024 Financial Results
May 15, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
May 08, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 19, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 18, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
April 18, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Expands Global Patent Portfolio
April 15, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Provides 2024 Clinical and Operational Update
April 02, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Reports Full Year 2023 Financial Results
March 08, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
March 01, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
February 21, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
January 10, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
December 14, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Reports Third Quarter 2023 Financial Results
November 15, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023
November 08, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia
October 24, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 08, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Reports Second Quarter 2023 Financial Results
August 15, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023
August 08, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
August 03, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia
August 01, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.